Cromos Pharma, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Dublin Ireland (2004)

Organization Overview

First Clinical Trial
2018
NCT03878004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

contract research organization Cromos Pharma | Cromos | Cromos, LLC, Tbilisi, Georgia | Cromos Pharma LLC | Cromos Pharma, LLC

Active Ingredients

Drugs in Phase 3 Trials (3)

aviptadil (1 trial)

iibr-100 (1 trial)

olokizumab (2 trials)

Drugs in Phase 2 Trials (1)

gamtbvac (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Infarction (Phase 2)

Inflammation (Phase 2)

Myocardial Infarction (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4